Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Solomon

Showing results (1181-1190 of 1,388) with videos related to

Pageof 139
Sort By:
Neurology|June 15, 2023
Global Barriers to the Diagnosis of Multiple Sclerosis: Data From the Multiple Sclerosis International Federation Atlas of MS, Third EditionAndrew J Solomon, Ruth Ann Marrie, Shanthi Viswanathan, et al.
Journal of Neurology|February 15, 2025
Multiple sclerosis diagnosis and its differential diagnosis in patients presenting with type four 'mirror pattern' CSF oligoclonal bandsDamiano Marastoni, Monica Sicchieri, Francesca B Pizzini, et al.
The European Respiratory Journal|January 17, 2025
Development and validation of a clinical, CT, genomic classifier and BAL scoring system for diagnosing idiopathic pulmonary fibrosisMichelle Li Wei Kam, Elysia L H Tjong, Sachin Chaudhary, et al.
The New England Journal of Medicine|November 18, 2020
First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i>-Positive Lung CancerAlice T Shaw, Todd M Bauer, Filippo de Marinis, et al.
Advances in Therapy|September 14, 2019
The Design and Rationale of the Trail1 Trial: A Randomized Double-Blind Phase 2 Clinical Trial of Pirfenidone in Rheumatoid Arthritis-Associated Interstitial Lung DiseaseJoshua J Solomon, Sonye K Danoff, Hilary J Goldberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 14, 2012
Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancerA T Shaw, A M Varghese, B J Solomon, et al.
The New England Journal of Medicine|December 4, 2014
First-line crizotinib versus chemotherapy in ALK-positive lung cancerBenjamin J Solomon, Tony Mok, Dong-Wan Kim, et al.
Lung Cancer (Amsterdam, Netherlands)|November 21, 2022
Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancerJulien Mazieres, Laura Iadeluca, Alice T Shaw, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 18, 2020
Prospective growth and developmental outcomes in infants born to mothers with multiple sclerosisTatenda Dawn Mahlanza, Maria Claudia Manieri, Eric C Klawiter, et al.
Future Oncology (London, England)|September 29, 2021
Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancerBenjamin J Solomon, Todd M Bauer, Filippo de Marinis, et al.
Pageof 139

Showing results (1181-1190 of 1,388) with videos related to

Sort By:
Pageof 139
Neurology|June 15, 2023
Global Barriers to the Diagnosis of Multiple Sclerosis: Data From the Multiple Sclerosis International Federation Atlas of MS, Third EditionAndrew J Solomon, Ruth Ann Marrie, Shanthi Viswanathan, et al.
Journal of Neurology|February 15, 2025
Multiple sclerosis diagnosis and its differential diagnosis in patients presenting with type four 'mirror pattern' CSF oligoclonal bandsDamiano Marastoni, Monica Sicchieri, Francesca B Pizzini, et al.
The European Respiratory Journal|January 17, 2025
Development and validation of a clinical, CT, genomic classifier and BAL scoring system for diagnosing idiopathic pulmonary fibrosisMichelle Li Wei Kam, Elysia L H Tjong, Sachin Chaudhary, et al.
The New England Journal of Medicine|November 18, 2020
First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i>-Positive Lung CancerAlice T Shaw, Todd M Bauer, Filippo de Marinis, et al.
Advances in Therapy|September 14, 2019
The Design and Rationale of the Trail1 Trial: A Randomized Double-Blind Phase 2 Clinical Trial of Pirfenidone in Rheumatoid Arthritis-Associated Interstitial Lung DiseaseJoshua J Solomon, Sonye K Danoff, Hilary J Goldberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 14, 2012
Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancerA T Shaw, A M Varghese, B J Solomon, et al.
The New England Journal of Medicine|December 4, 2014
First-line crizotinib versus chemotherapy in ALK-positive lung cancerBenjamin J Solomon, Tony Mok, Dong-Wan Kim, et al.
Lung Cancer (Amsterdam, Netherlands)|November 21, 2022
Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancerJulien Mazieres, Laura Iadeluca, Alice T Shaw, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 18, 2020
Prospective growth and developmental outcomes in infants born to mothers with multiple sclerosisTatenda Dawn Mahlanza, Maria Claudia Manieri, Eric C Klawiter, et al.
Future Oncology (London, England)|September 29, 2021
Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancerBenjamin J Solomon, Todd M Bauer, Filippo de Marinis, et al.
Pageof 139